biological mechanisms affecting race-specific cardiovascular and other clinical outcomes. The effects of such mechanisms independently of socioeconomic differences could have different impacts on various clinical outcomes as a result of distinct differences in the pathophysiology of each outcome. Atherosclerosis may have different pathophysiological underpinnings in blacks, who develop significantly less vascular calcification compared with white individuals, [16] [17] [18] [19] which may be the result of (among others) genetic differences in vitamin D and bone metabolism 8, 20 and could result in differences in cardiovascular morbidity and mortality. Blacks also experience a higher incidence of hypertension, more uncontrolled hypertension, and differences in central aortic blood pressure with potential consequences such as higher rates of left ventricular hypertrophy and stroke. 21 The relative contribution of these various factors to the disparities in outcomes seen in blacks and the extent to which they are affected by socioeconomic factors are not well defined and may vary according to the studied end point and the studied population segment. Furthermore, among the complex socioeconomic factors affecting race-specific outcomes in the United States, the relative contribution of poor access to health care is not well defined.
We hypothesized that blacks without advanced CKD or ESRD will have improved outcomes in a healthcare system that allows enrollment independently of race or socioeconomic status. The US Veterans Health Administration (VHA) is a healthcare system that does not impose the typical access barriers of the US healthcare system that may disproportionately impede enrollment of blacks. We compared all-cause mortality and incident cardiovascular event rates in a large contemporary cohort of black and white individuals with an estimated glomerular filtration rate (eGFR) ≥60 mL·min −1 ·1.73 m −2 followed up in any US VHA facility. We hypothesized that outcome differences between black and white veterans may be attenuated or eliminated by open healthcare access in US VHA facilities.
Methods

Study Design and Participants
We used data from a historic cohort study examining risk factors in patients with incident CKD (Racial and Cardiovascular Risk Anomalies in CKD [RCAV] study). 22 The algorithm for cohort definition is shown in Figure 1 . US veterans with serum creatinine measurements performed from October 1, 2004 , to September 30, 2006 were identified from the national Veterans Affairs (VA) Corporate Data Warehouse LabChem data files. 23 Overall, 4 447 691 veterans had at least 1 available serum creatinine measurement, representing ≈94% of all veterans who received VA health care during this time period. 24 eGFR was calculated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. 25 The RCAV cohort included 3 582 478 patients with eGFR ≥60 mL·min −1 ·1.73 m −2 , of whom we excluded 509 512 patients with race other than black or white (Hispanic, 73 105 [2.0%]; other races, 68 889 [1.9%]; and missing race, 365 489 [10.2%] ). The VA collects information on patients' race primarily from VA Form 10-10EZ (Application for Health Benefits), 26 which patients complete at enrollment and is updated as needed. We complemented this self-reported race with race data obtained from Medicare through the VA-Medicare data merge project. 26 In case of discrepancies, we used the race determination from Medicare because of its more accurate nature. 27 Our final analytic sample consisted of 3 072 966 patients (547 441 black and 2 525 525 white).
Sociodemographic Characteristics, Comorbidities, Medication Use, and Laboratory Variables
Information about sociodemographic characteristics, comorbid conditions, medication use, and laboratory characteristics was obtained as previously described. 28, 29 Briefly, data on patients' age, sex, marital status (married, single, divorced or widowed), mean per capita income, service connectedness (a measure indicating whether 1 or more of a patient's comorbidities were caused by military service, resulting in certain privileges such as preferential access to care and lower copayments), body mass index, systolic and diastolic blood pressures, comorbid conditions, location and frequency of healthcare encounters, and medication use were obtained from various national VA research data files. 30 28, 29 Prevalent coronary heart disease (CHD) was defined as the presence of diagnostic codes for coronary artery disease, angina, or myocardial infarction or procedure codes for percutaneous coronary interventions or coronary artery bypass grafting. We examined the use of 2 commonly applied medication classes (angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and statin-type cholesterol-lowering agents); use of healthcare interventions (influenza vaccinations and blood cholesterol level measurements) from October 1, 2004 , to September 30, 2006 ; and the yearly rate of healthcare encounters over the entire follow-up period to identify discrepancies in basic healthcare delivery. Other baseline characteristics were assessed on the date of cohort entry. In addition to data derived from VA sources, we included select socioeconomic indicators using 2004 county typology codes (housing stress, low education, low employment, and persistent poverty; see the Methods section in the onlineonly Data Supplement) based on the patients' residential address, obtained from the Area Health Resources Files system issued by the US National Center for Health Workforce Analysis, Bureau of Health Workforce, Health Resources and Services Administration (http:// ahrf.hrsa.gov/).
Outcomes
Outcomes of interest were all-cause mortality, incident CHD, and incident ischemic strokes. Deaths were ascertained from the VA Vital Status Files, the sensitivity and specificity of which (with the US National Death index used as gold standard) are 98.3% and 99.8%, respectively. 33 Incident CHD was defined as the composite of a first occurrence of an acute myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting; incident ischemic stroke was defined as the first occurrence of an ischemic stroke after October 1, 2006, in patients without such diagnoses before this date.
Statistical Analyses
Data are expressed as means ±SDs, medians (25th-75th percentiles), and proportions. Because of the large sample size, the significance of differences in the main cohort was established on the basis of what we deemed to be biologically or clinically meaningful differences. Differences between variables in the propensity-matched cohort were examined by calculating standardized differences and were regarded as significant if they were >0.1. The start of the follow-up period was the date of cohort entry, which was defined as the date of the first eGFR ≥60 mL·min −1 ·1.73 m −2 from October 1, 2004, to September 30, 2006. Patients were followed up until death or were censored at the date of the last healthcare or administrative VA encounter, as documented in the VA Vital Status Files, or on July 26, 2013. Sex-specific crude event rates were calculated from the number of event occurrences and patient-years during the follow-up period, and sex-specific age-adjusted event rates were calculated by the direct standardization method using the US 2000 Census data as the standard population October 20, 2015 (http://www.cdc.gov/nchs/tutorials/NHANES/NHANESAnalyses/ agestandardization/age_standardization_intro.htm).
The association of black race with the outcomes of interest was examined in univariable models and after multivariable adjustment. The association of covariates with outcomes was assessed in univariable analyses with the use of Kaplan-Meier curves and log-rank tests or with univariable Cox proportional hazards models and χ 2 tests, as appropriate. We included in multivariable models the covariates showing statistically significant associations with outcomes or those that could be associated with outcomes based on theoretical considerations. Cox models were applied to examine the effect confounders, with adjustments implemented incrementally. Model 1 was unadjusted; model 2, adjusted for age, sex, and baseline eGFR; model 3, model 2 variables plus prevalent comorbidities (diabetes mellitus, hypertension, CHD, congestive heart failure, cerebrovascular disease, peripheral vascular disease, chronic lung disease, peptic ulcer disease, hemiplegia, liver disease, dementia, rheumatic disease, malignancy, HIV/AIDS, and depression); model 4, model 3 variables plus baseline body mass index and systolic and diastolic blood pressures; and model 5, model 4 variables plus mean per capita income, marital status, service connectedness, housing stress, low education, low employment, persistent poverty, frequency of healthcare encounters, use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and statins, receipt of influenza vaccination(s), and each patient's VA healthcare center. Because of previous reports of marked differences in the outcomes of blacks with CKD, 14, 15 we further examined effect modification by decreased kidney function in subgroup analyses of patients who maintained eGFR ≥60 mL·min −1 ·1.73 m −2 throughout follow-up and in those who developed incident stage 3 and above CKD. 34 In the latter group, the start of follow-up was the date of eGFR used to define incident CKD. We further assessed whether the occurrence of incident CHD or stroke modifies the association of race with outcomes by including the incident events in the models as time-dependent variables and by including multiplicative interaction terms. Proportionality was tested by the use of Schoenfeld and scaled Schoenfeld residuals. We evaluated the fit of the model by using the Cox-Snell residuals.
Analyses were repeated in a propensity score-matched cohort. Propensity scores quantifying the likelihood of black versus white race were calculated by logistic regression, using all variables included in multivariable models and applying a 1-to-1 nearest neighbor matching without replacement in Stata's psmatch2 command suite. All outcomes were also examined in subgroups divided by baseline age, sex, prevalent CHD, congestive heart failure, diabetes mellitus, hypertension, eGFR, and income level. Unadjusted analyses for CHD and stroke were repeated in sensitivity analyses using competing risk regression, with nonevent deaths treated as competing events. 35 To compare outcomes associated with black versus white race in the VA system with those in the general population, we also performed an analysis of all-cause, cardiovascular, and stroke-related mortality overall in individuals with eGFR ≥60 mL·min −1 ·1.73 m −2 and in various subgroups using data from the NHANES 1999 to 2004 and adjusting all estimates for the complex NHANES survey design (online-only Data Supplement).
Statistical analyses were performed with STATA MP version 12 (STATA Corp, College Station, TX) and SAS version 9.3 (Research Triangle Park, NC). The study protocol was approved by the Research and Development Committees at the Memphis VA Medical Center and Long Beach VA Medical Center.
Results
The mean±SD baseline age of the cohort was 59.9±14.0 years, and 93.6% were men. Baseline characteristics in the overall cohort are shown in Table 1 . Compared with whites, blacks were younger, more likely to be female, service connected, hypertensive, and diabetic and to have HIV/AIDS. They were less likely to be married and to have prevalent CHD and chronic lung disease. Blacks also had more frequent healthcare encounters, higher systolic and diastolic blood pressures, and a lower per capita income and were more likely to live in areas with high housing stress, lower education level, and persistent poverty. The use of angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers and the administration of blood cholesterol measurements were similar in black and white veterans. The use of statins and the administration of influenza vaccinations were slightly less common in blacks. Blacks and whites had characteristics similar to each other in the propensity-matched cohort ( Table I in the onlineonly Data Supplement). Differences in baseline characteristics between black and white individuals (when available) were in general similar in the NHANES cohort and the VA cohort ( Table II in Table 2 shows sex-specific crude and age-adjusted mortality rates, indicating lower crude mortality rates in blacks for both men and women. This difference disappeared after adjustment for age in men and diminished but remained slightly lower in black women. Compared with whites, blacks had an overall crude mortality hazard ratio (HR) of 0.70 (95% CI, 0.69-0.71; P<0.001; model 1, Figure 2 ). Adjustment for age, sex, and baseline eGFR resulted in the attenuation of the black mortality advantage (model 2 HR, 0.99; 95% CI, 0.98-0.99; P<0.001), but further adjustment for additional covariates resulted in a gradual decrease in the mortality risk associated with black race (HR, 0.76; 95% CI, 0.75-0.77; P<0.001; model 5, Figure 2 ). Incident CHD and stroke modified the association between race and mortality. Compared with white patients who did not experience incident CHD or stroke, blacks without CHD or stroke had significantly lower mortality, whereas mortality rates in white and black patients after an incident CHD or stroke were similar and significantly higher compared with rates in patients without incident events ( Figure 2 ). (14) Living in area with low employment, n (%) 275 108 (9) 218 818 (9) 56 290 (11) Living in area of persistent poverty, n (%) 275 108 (5) 102 782 (4) 37 247 (7) Data are presented as mean±SD, median (25th-75th percentiles), or number (percent of total). ACEI/ARB indicates angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; BMI, body mass index; CHD, coronary heart disease; CHF, chronic heart failure; CVD, cerebrovascular disease; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; PAD, peripheral arterial disease; and SBP, systolic blood pressure. October 20, 2015
Adjusted all-cause mortality was higher in black versus white individuals both overall (HR, 1.51; 95% CI, 1.19-1.92) and in individuals with eGFR ≥60 mL·min −1 ·1.73 m −2 in NHANES (HR, 1.42; 95% CI, 1.09-1.87; Figure 3 ). Mortality in NHANES was also higher in blacks versus whites categorized by age (adjusted HR for age 18 . Cardiovascular and stroke-related mortality was similar in blacks and whites in NHANES, although the low number of stroke events resulted in imprecise risk estimates (Figure 3 ).
Incident CHD
A total of 63 808 patients experienced an incident CHD event (crude rate, 3.43 per 1000 patient-years; 95% CI, 3.40-3.46), with 53 988 events in whites (crude rate, 3.60 per 1000 patient-years; 95% CI, 3.57-3.63) and 9820 events in blacks (crude rate, 2.73 per 1000 patient-years; 95% CI, 2.68-2.79). Incident CHD rates in blacks versus whites were lower in both men and women after adjustment for age ( Table 2 ). Both crude (HR, 0.75; 95% CI, 0.74-0.77) and adjusted (HR, 0.63; 95% CI, 0.62-0.65) risks of incident CHD and of the individual components (acute myocardial infarction, coronary artery bypass grafting, and percutaneous coronary intervention) were lower in blacks (Figure 4 ). The risk of incident CHD was higher in individuals after strokes compared with those who did not have an incident stroke, but incident strokes did Association of black race with all-cause mortality in the overall cohort of 3 072 966 veterans. A, Association of black race with all-cause mortality in the overall cohort with adjustments for baseline characteristics. White patients served as referent. B, Associations of race with all-cause mortality in patients with and without an incident coronary heart disease (CHD) event. CHD events were entered into the models as time-dependent covariates, and models were estimated by including multiplicative interaction terms between race and CHD events. White patients without incident CHD served as referent. C, Associations of race with all-cause mortality in patients with and without incident strokes. Strokes were entered in the models as time-dependent covariates, and models were estimated by including multiplicative interaction terms between race and strokes. White patients without incident strokes served as referent. Model 1, unadjusted; model 2, adjusted for age, sex, and baseline estimated glomerular filtration rate; model 3, model 2 variables plus comorbidities; model 4, model 3 variables plus baseline body mass index and systolic and diastolic blood pressures; and model 5, model 4 variables plus mean income, marital status, service connectedness, area-level housing stress, low education, low employment, persistent poverty, frequency of Veterans Affairs (VA) healthcare encounters, use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and statins, receipt of influenza vaccination(s), and each patient's VA healthcare center. AA indicates African American; and CI, confidence interval. not modify the association between race and incident CHD, which remained lower in black versus white patients with or without incident strokes (Figure 4 ).
Incident Stroke
In total, 59 734 patients experienced an incident stroke (crude rate, 3.02 per 1000 patient-years; 95% CI, 2.99-3.04), with 46 984 events in whites (crude rate, 2.91 per 1000 patient-years; 95% CI, 2.88-2.93) and 12 750 events in blacks (crude rate, 3.49 per 1000 patient-years; 95% CI, 3.43-3.55). Incident stroke rates in blacks versus whites remained higher in both men and women after adjustment for age ( Table 2 ). Crude stroke risk was higher in blacks (HR, 1.18; 95% CI, 1.16-1.21), but this was attenuated after multivariable adjustments, especially for socioeconomic characteristics in model 5 (HR, 0.99; 95% CI, 0.97-1.01; Figure 5 ). Incident CHD did not modify the association between race and incident stroke, which was similar in black and white patients with or without CHD, even though the risk of stroke was higher in patients who experienced an incident CHD event compared with those who did not ( Figure 5 ).
Sensitivity Analyses
The mortality risk associated with black race was also lower in propensity score-matched analyses (HR, 0.86; 95% CI, 0.85-0.87; Table III in The risk of incident CHD was lower in blacks versus whites in the overall propensity-matched cohort (HR, 0.68; 95% CI, 0.66-0.70; Table III in Stroke risk was also higher in blacks in the overall propensity-matched cohort (HR, 1.09; 95% CI, 1.06-1.12; Table III in the online-only Data Supplement), in patients who developed incident CKD (HR, 1.17; 95% CI, 1.10-1.24), and in those who maintained eGFR ≥60 mL·min −1 ·1.73 m −2 (HR, 1.05; 95% CI, 1.02-1.09; Figures V and VI in the online-only Data Supplement), as well as in competing-risk regression ( Table IV in the online-only Data Supplement). Blacks experienced higher stroke risk among older individuals and women and in subgroups with prevalent CHF, lower eGFR, and lower income ( Figure 6 ).
Discussion
In this large cohort of >3 million contemporary US veterans with baseline eGFR ≥60 mL·min −1 ·1.73 m −2 , we found significant differences in major clinical outcomes between blacks and whites not traditionally reported in the general population. We found substantially lower incident CHD rates and, most surprising, lower all-cause mortality in blacks compared with whites. Differences in demographic, comorbidity, and socioeconomic characteristics accounted for some but not all of the difference in mortality and CHD. Contrasting the lower mortality seen in US veterans, our analyses of NHANES 1999 to 2004 showed higher all-cause mortality in blacks versus whites. Similar to previous reports, 36 incident stroke rates were higher in black veterans, but differences were attenuated to nonsignificant after adjustment for socioeconomic characteristics.
Worse health outcomes in blacks have been well described. 37 These have included a variety of outcomes transcending age and sex categories. [2] [3] [4] [5] [6] The socioeconomic deprivation of blacks has provided a plausible explanation for these observations 7 and points to the importance of breaking down the many remaining barriers faced by the black community. In today's typical US healthcare environment, it is difficult to separate the effects on outcomes of poor healthcare access and race-based discrimination in healthcare delivery from the effects of biological mechanisms. This would require not only an egalitarian healthcare system but also a society that does not directly or indirectly discriminate. In a community-based standardized healthcare system, Karter et al 38 Previous studies examining all-cause mortality in hospitalized patients 40 and outcomes associated with various health conditions such as congestive heart failure, 41 Pneumocystis carinii pneumonia, 42 and colorectal and lung cancer 43, 44 have also reported better outcomes in black veterans compared with those typically seen in nonveterans. Furthermore, our examination of basic healthcare metrics such as the administration of common health screening procedures and medications suggests that basic health care delivered after enrollment in a contemporary VHA facility is not racially discriminatory. Also supporting this notion, a previous study examining unmet healthcare needs in patients of various races and ethnicities showed that the use of VA ambulatory care eliminated the disparity in the ability to obtain needed healthcare services between black and white veterans. 45 Finally, among participants in the UK Prospective Diabetes Study (UKPDS), Afro-Caribbean patients experienced substantially reduced risk of all-cause and diabetes-related mortality, myocardial infarctions, but not strokes, 46, 47 suggesting that receiving similar care in a controlled system outside the United States may also result in benefits for minorities that are similar to those reported in our study.
One possible explanation for the observed racial discrepancies in outcomes is the biological differences between blacks and whites that are overwhelmed by the socioeconomic disparities in the general population but uncovered in a system that provides open access to health care. There is now mounting evidence that some blacks have distinctly unique genetic characteristics linked to their African ancestry that have a direct impact on health outcomes. 8 Aside from the above-mentioned common genetic polymorphisms responsible for excess CKD and ESRD in blacks, [9] [10] [11] [12] [13] there may be additional ones affecting cardiovascular pathophysiology and outcomes. [48] [49] [50] We limited our analysis to patients with eGFR ≥60 mL·min −1 ·1.73 m −2 to examine patients in whom clinical outcomes would less likely be affected by genetic differences leading to kidney disease or the biological effect of azotemia, which could directly or indirectly affect the lower mortality previously described by us in black veterans with CKD. 15 Our results showing lower mortality and CHD incidence but higher stroke incidence in blacks independently of their level of eGFR suggest that such differences could be a result of genetic or other differences in susceptibility to various cardiovascular processes. Recent findings that blacks experience significantly less vascular calcification compared with white individuals, [16] [17] [18] [19] perhaps owing to genetic differences in various physiological processes such as vitamin D and bone metabolism, 8, 20 support such a hypothesis. Other race-specific biological differences that could affect other cardiovascular outcomes such as strokes include a higher incidence of hypertension, more uncontrolled hypertension, and differences in central aortic blood pressure and prevalence of left ventricular hypertrophy in blacks. 21 The presence of divergent clinical outcomes (lower CHD incidence but higher stroke incidence) could be indicative of distinctly different biological processes underlying these outcomes, with some portending a favorable Figure 6 . Association of black race with various outcomes in predefined subgroups of the overall cohort of 3 072 966 veterans. White patients served as referent. Models were adjusted for age, sex, baseline estimated glomerular filtration rate (eGFR), comorbidities, baseline body mass index, systolic and diastolic blood pressures, mean income, marital status, service connectedness, area-level housing stress, low education, low employment, persistent poverty, frequency of Veterans Affairs (VA) healthcare encounters, use of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and statins, receipt of influenza vaccination(s), and each patient's VA healthcare center. CHD indicates coronary heart disease; CHF, congestive heart failure; CVD, cardiovascular disease; DM, diabetes mellitus; and HTN, hypertension. October 20, 2015 but others an unfavorable outcome in blacks. Our finding that mortality after incident cardiovascular events in our cohort was similar in blacks and whites and the lack of difference in cardiovascular and stroke-related mortality between blacks and whites in NHANES suggest that most of the race-based differences could affect the development of cardiovascular lesions, and less so their secondary deleterious consequences.
Our study is notable for the very large number of studied individuals and for its US-wide distribution. Our study also has several limitations. Our cohort consisted predominantly of men; hence, our conclusions may not apply to women. Previous studies have described important sex differences in race-based outcomes. 51 However, our findings were similar in female compared with male veterans, and despite the low percentage of women in our cohort, their absolute number was substantial (>150 000 patients) and eclipsed the number of women examined in most or all previous studies. We used self-identified race as our predictor, which is biologically inferior to gene-based determination of ancestry; however, the former captures social constructs and the latter method is not yet available for large-scale epidemiological studies. Our cohort consisted of US veterans with distinct demographic and clinical characteristics; hence, it is unclear whether our findings can be applied to nonveterans. Enrollment in the US armed services and subsequently into the VHA may include distinct populations of blacks and whites. Although we cannot discount this possibility, the basic characteristics of our cohort suggest that differences between blacks and whites seen in the general population were indeed present in our cohort (eg, differences in income, marital status, and certain comorbidities). Thus, it is less plausible that the observed differences in outcomes were due solely to selection bias. Furthermore, higher stroke rates 52 and lower incidence of CHD 47, 51 in populations of African ancestry have previously been reported in nonveterans, which also suggests that our findings are not limited to US veterans alone. We examined clinical events recorded during care received in a VA facility and would not have captured similar events recorded at non-VA facilities. We captured clinical events using diagnostic codes, not the more accurate adjudication procedures used in clinical trials, which are not feasible in a study of this size. However, these limitations do not apply to all-cause mortality. We examined all-cause mortality because we had no information about causes of death. We adjusted for a variety of demographic, social, economic, and healthcare-quality indexes that could affect race-based differences in care, but we cannot exclude the possibility that unmeasured confounders may also play a role in the observed differences. We defined our cohort on the basis of an eGFR ≥60 mL·min −1 ·1.73 m −2 , but we did not have markers of earlier stages of CKD (eg, proteinuria). We imply that the described associations are present in the overall VA population regardless of level of kidney function using separate analyses in patients with eGFR ≥60 and <60 mL·min −1 ·1.73 m −2 but without analyzing all VA-enrolled patients as a single cohort.
Conclusions
There are significant differences in major clinical outcomes experienced by black patients enrolled in an open-access healthcare system (US VHA) compared with their white counterparts. Black veterans experienced a lower incidence of CHD, higher incidence of stroke, and lower all-cause mortality compared with white veterans. Differences in mortality and in incident CHD could not be explained by differences in demographic, comorbidity, and socioeconomic characteristics, suggesting that there may be important sociocultural or evolutionary transmitted biological differences (eg, neurohormonal, epigenetic, gene variants) explaining the development of cardiovascular or other diseases in individuals of different races. Future studies will need to elucidate the nature of such putative differences to determine whether race-specific measures are needed for the prevention and treatment of cardiovascular disease.
